SERANasdaqServices-Medical LaboratoriesFiscal year ends December 31
SERA PROGNOSTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.03−0.03 (-1.46%)
Close on Oct 19, 2026
- Market cap
- $102.47M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
-102.5%
Operating margin
-45066.7%+26817.3 pts over 5 years
Net margin
-39417.3%+39974.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.2% | -32.9% | +26.5% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 17.1% | -51.8% | |
| Return on assets | – | – | -36.6% | |
| Current ratio | – | 1.22 | 1.69 | |
| Interest coverage | – | – | -4056.0× | |
| Capex to revenue | – | 596.0% | 896.3% | |
| Diluted shares | – | 2M | 48M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sera Prognostics generated $133.25M from operations and spent $3.01M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$133.25M
Used
$3.01M
Capital expenditure$3.01M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-39417.3%
×Asset turnover0.00×
×Equity multiplier1.42×
=Return on equity, FY2025-51.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -39417.3% | 0.00× | 1.42× | -51.8% |
| FY2024 | -42724.7% | 0.00× | 1.42× | -55.8% |
| FY2023 | -11843.8% | 0.00× | 1.25× | -42.9% |
| FY2022 | -16487.3% | 0.00× | 1.11× | -37.2% |
| FY2021 | -42693.9% | 0.00× | 12.45× | -538.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$31.93M
- Cash generatingOperating cash flow above zero-$25.62M
- Return on assets improvedROA up on the prior year-34.5% → -44.0%
- Earnings backed by cashOperating cash flow above net income-$25.62M vs -$31.93M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.92 → 1.69
- No dilutionShare count did not rise33M → 48M
- Gross margin improvedGross margin up on the prior year-6.49% → -102.47%
- More efficientAsset turnover rose0.00 → 0.00